Synthesis and preclinical evaluation of tigilanol tiglate analogs as latency-reversing agents for the eradication of HIV
Science Advances · 24.01.2025 · 11 (4)
DOI: 10.1126/sciadv.ads1911 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 24.01.2025. Verfasst von Zachary O Gentry und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Stanford University, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: HIV Infections, Virus Latency, HIV-1, Anti-HIV Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Tigilanol tiglate (EBC-46) is a selective modulator of protein kinase C (PKC) isoforms that is Food and Drug Administration (FDA) approved for the treatment of mast cell tumors in canines with up to an 88% cure rate. Recently, it has been FDA approved for the treatment of soft tissue sarcomas in humans. The role of EBC-46 and, especially, its analogs in efforts to eradicate HIV, treat neurological and cardiovascular disorders, or enhance antigen density in antigen-targeted chimeric antigen receptor–T cell and chimeric antigen receptor–natural killer cell immunotherapies has not been reported. Enabled by our previously reported scalable synthesis of EBC-46, we report herein the systematic design, synthesis, and evaluation of EBC-46 analogs, including those inaccessible from the natural source and their PKC affinities, ability to translocate PKC, nuclear factor κB activity, and efficacy in reversing HIV latency in Jurkat-Latency cells. Leading analogs show exceptional PKC affinities, isoform selectivities, and functional activities, serving as promising candidates for therapeutic applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Stanford University, Stanford, CA 94305, USA.
- Department of Biology, Stanford University, Stanford, CA 94305, USA.
- Department of Microbiology & Molecular Genetics, School of Medicine, University of California Irvine, Irvine, CA 92697, USA.
- Department of Medicine, Division of Infectious Diseases, University of California Los Angeles, Los Angeles, CA 90095, USA.
- Department of Medicine (Division of Infectious Diseases), School of Medicine, University of California Irvine, Irvine, CA 92697, USA.
- Department of Microbiology, Immunology, and Molecular Genetics, University of California Los Angeles, Los Angeles, CA 90095, USA.
ORCID-Profile: Zachary O Gentry, Owen D McAteer, Jennifer L Hamad, Jose A Moran, Jocelyn T Kim, Matthew D Marsden, Jerome A Zack, Paul A Wender
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Gentry, Z. O., McAteer, O. D., Hamad, J. L., Moran, J. A., Kim, J. T., Marsden, M. D., Zack, J. A., & Wender, P. A. (2025). Synthesis and preclinical evaluation of tigilanol tiglate analogs as latency-reversing agents for the eradication of HIV. Science Advances, 11(4). https://doi.org/10.1126/sciadv.ads1911
Vancouver
Gentry ZO, McAteer OD, Hamad JL, Moran JA, Kim JT, Marsden MD, et al. Synthesis and preclinical evaluation of tigilanol tiglate analogs as latency-reversing agents for the eradication of HIV. Science Advances. 2025;11(4). doi:10.1126/sciadv.ads1911
BibTeX
@article{Gentry2025,
author = {Gentry, Zachary O and McAteer, Owen D and Hamad, Jennifer L and Moran, Jose A and Kim, Jocelyn T and Marsden, Matthew D and Zack, Jerome A and Wender, Paul A},
title = {Synthesis and preclinical evaluation of tigilanol tiglate analogs as latency-reversing agents for the eradication of HIV},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {4},
doi = {10.1126/sciadv.ads1911}
}
EUVIMED